Purpose of review Methicillin-resistant Staphylococcus aureus (MRSA) has become a major public health issue worldwide over the last years. MRSA is frequently implicated in the development of skin and soft tissue infections, leading to significant increases in morbidity, mortality and overall healthcare costs.
INTRODUCTION
Staphylococcus aureus is the most frequently isolated pathogen in complicated skin and soft tissue infections (cSSTIs) worldwide, accounting for up to 50% of isolates [1, 2] . The progressive increase in methicillin resistance during the last years represented a major threat in clinical practice, leading to high rates of inadequate antibiotic treatment and significant increases in morbidity, mortality and overall healthcare costs [3, 4] . In order to face the threat of methicillin-resistant Staphylococcus aureus (MRSA), a number of new therapeutic options with specific activity against MRSA have been recently developed and approved for the treatment of cSSTIs. However, data supporting the use of new agents come mainly from registrative studies designed as noninferiority trials, whereas no evidence of superiority of new agents over standard treatment has been demonstrated so far. Therefore, the introduction of new agents into the everyday clinical practice still represents a challenge, also because of the higher costs of new molecules compared with the traditional antibiotics with activity against MRSA (e.g., vancomycin). New anti-MRSA agents can also present limitations in spectrum of activity, pharmacokinetics, drug-drug interactions and toxicity that should be taken into account in clinical practice.
Here we analyze the epidemiology of MRSA in cSSTIs in clinical practice, and we present a potential strategy for optimizing empiric and targeted treatment in MRSA cSSTIs, taking also into account new available therapeutic options.
EPIDEMIOLOGY OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
During last years, alarming rates of methicillin resistance in S. aureus have been reported worldwide [5, 6] . In the majority of countries, including the United States, Latin America, sub-Saharan Africa, Russia, India and China, up to 25% of S. aureus isolates were reported to display methicillin resistance in the recent Centre for Disease Dynamics, Economics and Policy report [7] . Similar data have been reported by the European Antimicrobial Resistance Surveillance Network in 2014, showing approximately 18% of MRSA isolates in Europe, although a wide regional variability was reported ranging from less than 1% in northern Europe to 25% in areas of southern Europe including Spain, Portugal, Italy and Greece [6] .
In cSSTIs, MRSA plays an important role. The large SENTRY Antimicrobial Surveillance Program has been monitoring the epidemiology of SSTIs over a 7-year period (1998) (1999) (2000) (2001) (2002) (2003) (2004) in three continents (North America, South America and Europe), reporting S. aureus as the most common isolate worldwide with 20-30% of MRSA in Europe and Latin America and up to 35% in North America [1] . Another large study encompassing over 3000 cSSTI-associated isolates from 19 countries in Europe found S. aureus in almost one-third of cases and approximately onehalf of those were MRSA [8] .
The burden of MRSA is still more prominent in hospital compared with the community setting [9] [10] [11] . In recent years, however, MRSA has progressively spread into the community, particularly among outpatients affected by multiple comorbidities and having frequent contact with the healthcare system (e.g. residing in a nursing home or long-term-care facility; recent hospitalizations; hemodialysis or intravenous chemotherapy; and wound care or enteric nutrition at home), thus expanding the population at risk for the acquisition of MRSA infection [12] [13] [14] .
Community-acquired (CA)-MRSA represents a concern [15] . CA-MRSA is characterized by peculiar epidemiology, clinical features and genetic characteristics, delineating a specific clinical entity that should be considered distinct from the classical cSSTIs because of hospital-acquired (HA)-MRSA. CA-MRSA is typically involved in the development of epidemic and recurrent episodes of acute bacterial SSTIs in young and healthy patients, and usually occurs in closed communities such as military establishments, prisons and among athletes. Patients usually do not present significant comorbidities or contacts with healthcare system [15] . CA-MRSA frequently encodes the genes for Panton-Valentine leukocidin and a wide spectrum of other exotoxins, leading to a higher virulence compared with HA-MRSA and resulting in high disease severity and possible tissue necrosis [16] . As compared to HA-MRSA, which tends to be multiresistant, CA-MRSA is usually susceptible to narrow-spectrum non-b-lactams such as fluoroquinolones, clindamycin, trimethoprim-sulfamethoxazole and tetracyclines [16] . CA-MRSA epidemiology varies geographically, representing a major threat in United States [17, 18] , whereas in Europe it is currently less commonly reported [19, 20] .
RISK FACTORS FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACQUISITION
The prompt identification of the population at risk for the development of MRSA cSSTIs is crucial in order to reduce the risk of prescribing an inappropriate empiric antibiotic treatment. Unfortunately, the large majority of risk factors for MRSA infections are not well defined, and no algorithms allowing the identification of patients with cSSTIs due to MRSA are currently available. In a recent study, CallejoTorre et al. [21] attempted to identify risk factors for MRSA colonization and/or infection in a large retrospective cohort encompassing approximately 70 000 patients admitted to 147 ICUs in Spain in the period 2006-2010. In this setting, skin and soft tissue and postsurgical skin infections were independently associated with the isolation of MRSA.
Nasal and skin MRSA colonization has been recently pointed out as a major risk factor for the development of cSSTIs, both in hospital and in the community [22, 23] . In particular, recent data by Gunderson et al. [24] found that nasal MRSA colonization at hospital admission predicted the
KEY POINTS
The role of MRSA in skin and soft tissue infections has progressively grown over the last years, causing significant increases in morbidity, mortality and healthcare costs.
Changes in clinical management of patients with complicated skin and soft tissue infections should be considered, in particular in areas with high MRSA prevalence.
The identification of risk factors for MRSA infections along with the improvement of diagnostic techniques is of paramount importance.
New antibiotics with activity against MRSA are expected to have many advantages in clinical practice, with potential benefits in terms of morbidity, mortality and overall healthcare costs.
Novel antibiotics characterized by oral formulation or weekly administration may allow early discharge and outpatient treatment. development of MRSA cSSTIs, particularly in high prevalence populations. Moreover, environmental contamination has been proven to play a key role in the development of MRSA cSSTI recurrent infections [25] . However, it may be challenging to translate these findings into the wide clinical practice, as nasal swabs to identify MRSA carriage status are not performed routinely at hospital admission, and no recommendation can be made in this regard so far. Risk factors for the development of cSSTIs caused by MRSA are summarized in Table 1 .
MRSA in skin infections

THERAPY OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS
The association between inappropriate antibiotic therapy, treatment failure and impaired clinical outcomes in cSSTIs is well recognized.
Berger et al. [26] analyzed data from 100 hospitals in the United States over 9 years and tried to analyze the consequences of initial antibiotic failure in patients hospitalized for cSSTIs. The rate of initial treatment failure was 16.6% in acute infections, 34.1% in chronic/ulcerative infections and 26.7% in surgical site infections. Treatment failure was associated with significant increase in hospital stay (4.1-7.3 additional days); moreover, the case fatality rate was four-fold to 12-fold higher in patients who experienced treatment failure compared with those who did not (P < 0.01). Similar data have been recently reported by Ostermann et al. [27] with increment up to 10 days of hospital stay among patients admitted with cSSTIs and requiring modification of initial antibiotic treatment.
For these reasons, the recent Infectious Disease Society of America guidelines highlighted how early and adequate antibiotic treatment together with prompt source control represents key points for clinical management of cSSTIs [28] . Moreover, disease severity should be taken into consideration because of its strong association with mortality [29, 30] .
EMPIRIC TREATMENT
Recent data showed that empiric antibiotic therapy has changed over the last years, with a substantial increase in the prescription of antimicrobials with anti-MRSA activity [31 & ]. The REACH study analyzed current management practices in patients hospitalized with cSSTIs in 129 sites in Europe showing that, even if up to 20% of cSSTIs were caused by MRSA, only a minority of patients received an empiric anti-MRSA antimicrobial regimen, with penicillins and penicillins and b-lactamase inhibitors being the most common regimens [1, 32] . Initial antibiotic regimen modification was required in approximately 40% of patients mainly because of treatment failure [32] . Moreover, in a recent study, the isolation of MRSA was significantly associated with treatment failure in cSSTIs admitted to the emergency department unit [33] .
For these reasons, in areas with high MRSA prevalence, the prescription of an early broad-spectrum empiric therapy followed by a prompt deescalation upon availability of microbiological data should be strongly recommended in severe infections requiring hospitalization and when risk factors for MRSA are present. Conversely, a de-escalation approach should be limited to mild infections without risk factors for resistant pathogens.
VANCOMYCIN
Vancomycin still represents the most used antimicrobial with anti-MRSA activity worldwide [28] . However, vancomycin requires a twice-daily intravenous administration, not allowing the treatment of outpatients, and therapeutic drug monitoring is needed in order to minimize the risk of nephrotoxicity and ensure the achievement of adequate plasmatic concentrations [34] . Vancomycin efficacy has recently been questioned because of the progressive increase in vancomycin minimum inhibitory concentrations (MICs) in MRSA (MIC-creep), and the choice of an alternative antibiotic regimen is recommended when vancomycin MIC is greater than 1 mg/l [35] . Daptomycin currently represents an attractive alternative to vancomycin for the ]. A recent meta-analysis suggested that daptomycin might be superior in terms of efficacy compared with vancomycin for the treatment of cSSTIs, although no randomized controlled trials confirming this result are currently available [38] . The optimal dosage of daptomycin is still debated; the standard daily dose of 4 mg/kg may be considered inappropriate on the basis of recent data, leading to reduced clinical efficacy and increased risk of resistance selection [39] [40] [41] . A daily dose of at least 6 mg/kg is recommended for the treatment of cSSTIs, with higher doses (up to 10 mg/kg/day) strongly suggested in bacteraemia and/or endocarditis and when daptomycin MICs are more than 0.25 [42 && ].
CEFTAROLINE
Ceftaroline is the first b-lactam antimicrobial with activity against MRSA and is currently approved in the United States and Europe for the treatment of severe cSSTIs and community-acquired pneumonia in adults at the dose of 600 mg twice daily. The major advantage of ceftaroline consists of a broad-spectrum and bactericidal activity against both Gram-positive bacteria, including MRSA with reduced susceptibility to vancomycin and b-lactamresistant Streptococcus pneumoniae and Gramnegative bacteria, with the exception of Pseudomonas aeruginosa and extended-spectrum b-lactamaseproducing Enterobacteriacae [ ]. Ceftaroline represents a promising option for the empiric treatment of severe cSSTIs when the risk of polymicrobial infections and MRSA involvement is high, for example in diabetic patients and traumatic wound infections. The role of ceftaroline in diabetic foot infections (DFIs) is supported by the recent CAPTURE study, showing good clinical outcomes in up to 80% of cases, including MRSA infections and previous treatment failure [47] . A major limitation for empiric use of ceftaroline is the lack of activity against P. aeruginosa, which represents common isolate in polymicrobial cSSTIs infections, DFIs and chronic ulcers.
CEFTOBIPROLE
Ceftobiprole, which displays a spectrum of activity similar to ceftaroline with the difference of being effective also against P. aeruginosa, represents an interesting option for the treatment of cSSTIs. However, ceftobiprole is currently approved in Canada and in 13 countries in Europe for treatment of adults with community-acquired and hospital-acquired pneumonia, with the exception of ventilator-associated pneumonia. Despite data coming from phase III trials supporting the use of ceftobiprole for the treatment of cSSTIs, the drug failed to gain approval for this indication from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) so far [48] .
TIGECYCLINE
When a polymicrobial infection (e.g. DFI and chronic ulcer) is suspected in patients with risk factors for MRSA and/or extended-spectrum b-lactamase-producing Enterobacteriaceae, tigecycline might represent a good option for empiric treatment, with the limitation not to be effective against P. aeruginosa [49, 50] .
DE-ESCALATION AND TARGETED TREATMENT FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS
In patients with cSSTIs, a prompt de-escalation based on microbiological data, with the prescription of a narrow-spectrum antimicrobial of an oral agent, has been associated with significant reduction in the length of treatment and hospital stay as well as overall healthcare costs [51] . For this reason, whenever possible, an 'early de-escalation, early discharge' approach should be recommended.
Nevertheless, in Europe, de-escalation is currently applied in less than one-third of cases [32] . Moreover, the overall length of stay is generally longer than required for achieving clinical stability, with a median length of stay of 18 days in patients with cSSTIs [32] .
In settings with high MRSA prevalence, two main factors limit a rapid de-escalation and early discharge. First, a microbiological diagnosis with susceptibility test, which frequently represents the trigger for de-escalation in clinical practice, is difficult to achieve. Blood cultures are positive in less than 10% of cases and superficial swabs are not useful for discriminating between colonization and infection, with biopsy and culture from purulent collections representing the most useful samples. Overall, a microbiological diagnosis is obtained in less than 50% of cases, even if an adequate microbiological culture is performed [32] . Second, the only agent with anti-MRSA activity available as an oral formulation is linezolid, which currently represents the first choice for de-escalation because of the high volume distribution, good tissue penetration and low resistance rates [52] . Moreover, linezolid treatment has been associated with significant reductions in both length of stay and treatment duration compared with vancomycin [53, 54] , and a recent meta-analysis demonstrated linezolid to be more effective than vancomycin for the treatment of cSSTIs in terms of clinical and microbiological cure rates, including infections due to MRSA [55] . Linezolid use, however, has some limitations in clinical practice. The most important problem is the potential risk of hematological side-effects, mainly thrombocytopenia, which is particularly relevant in patients with treatment duration exceeding 2 weeks and/or a plasmatic exposure above 8 mg/l [56, 57] ; for this reason, therapeutic drug monitoring would be beneficial in patients receiving linezolid, but it is available in clinical practice only in a minority of sites [58] . Furthermore, due to the inhibition of mono-amino-oxidase enzymes, linezolid should be used with caution in association with drugs with serotoninergic activity for the risk of development of serotoninergic syndrome [59] .
NEW ANTIMICROBIALS FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT
A number of new agents with anti-MRSA activity have been recently developed, with the potential to deeply impact the management of cSSTIs in clinical practice in the near future.
TEDIZOLID
Tedizolid is a new-generation oxazolidinone currently approved by FDA and EMA for the treatment of cSSTIs. The spectrum of activity of tedizolid is similar to linezolid, but with a four-fold to eightfold greater activity against a broad spectrum of Gram-positive pathogens, including linezolid-resistant strains [60] . The major advantages of tedizolid over linezolid are the lower risk of myelotoxicity [61, 62] and drug-drug interactions with compounds with serotoninergic activity and adrenergic agents, because of a weak and reversible in-vitro inhibition of the monoamine oxidase pathway [63] . Moreover, tedizolid half-life is approximately two-fold greater compared with linezolid, allowing once-daily administration [64] . For these reasons, tedizolid may represent a good option for early therapy de-escalation in patients with underlying hematological alterations and/or potential drugdrug interactions.
LIPOGLYCOPEPTIDES
Another attractive option for the treatment of cSSTIs due to MRSA is represented by three new lipoglycopeptides (dalbavancin, oritavancin and telavancin), which have been proved noninferior versus vancomycin in phase III, double blinded, controlled trials [65] [66] [67] . All of these three compounds provide a rapid, concentration-dependent bactericidal activity against a broad-spectrum of Gram-positive pathogens, including MRSA [68, 69] .
Oritavancin has been approved in Europe for the treatment of cSSTIs in January 2015. The recommended dose is single, intravenous dose of oritavancin (1200 mg) administered as a 3-h infusion.
Dalbavancin has been approved by the US FDA for the treatment of cSSTIs in May 2014 and by the EMA in March 2015 with a two-dose regimen of 1000 mg followed after 1 week by 500 mg, each administered over 30 min. However, a recently published randomized controlled trial by Dunne et al. [70] demonstrated that a single 1500 mg infusion of dalbavancin was not inferior to the two-dose regimen, with similar safety profile.
Both oritavancin and dalbavancin are well tolerated, with few side-effects, mostly represented by nausea, vomiting, diarrhea and headache [65, 66] .
Allowing a single-dose administration, both oritavancin and dalbavancin might represent good options for early hospital discharge and good clinical response in 72 h favoring reductions in the length of stay and overall costs.
Currently recommended doses, advantages, disadvantages and suggested use in clinical practice of newly approved and investigational antimicrobials Good tolerability profile DFI, diabetic foot infection; ESBL, extended-spectrum b-lactamase; IV, intravenously; TDM, therapeutic drug monitoring.
with activity against MRSA in patients with suspected or confirmed cSSTI are summarized in Table 2 .
CONCLUSION
MRSA represents a major concern in cSSTIs. In order to face the challenge of MRSA, improvements in patients' stratification for potential risk factors and prompt diagnostic techniques should be sought.
New antibiotic agents present a number of favorable characteristics that may lead to potential advantages in the management of cSSTIs into the wide clinical practice, with potential benefits in terms of reduction of morbidity, mortality and overall healthcare costs.
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